figure
posted on 2025-08-20, 07:40 authored by Samantha I. Liang, Zoe Quandt, Sara Wienke, Jing Wang, Sean Gordon, Reagan M. Barnett, Jude Masannat, Kyle Chang, Carin R. Espenschied, Katie J. Quinn, Kimberly C. Banks, Enjun Yang, John E. Connolly <p><b>A</b> and <b>B,</b> Candidate thresholds for TF change indicating MR and nMR among the patients in whom either T0 or T1 were quantifiable (<i>n</i> = 459). <b>A,</b> Forest plot for various TF changes (<b>B</b>) Kaplan–Meier analysis of rwPFS by select candidate thresholds across the full dataset. Log-rank test between groups: 100% vs. any decrease, <i>P</i> < 0.005; 80% decrease vs. any decrease, <i>P</i> = 0.01; 100% decrease vs. 80% decrease, <i>P</i> = 0.04; 100% decrease vs. any increase, <i>P</i> < 0.005; 80% decrease vs. any increase, <i>P</i> < 0.005; any decrease vs any increase, <i>P</i> < 0.005. c-index, concordance index.</p>
History
ARTICLE ABSTRACT
Current response evaluation methods have accuracy limitations. Monitoring with a ctDNA methylation-based tumor fraction (TF) may provide a more accurate assessment of tumor burden across solid tumors. In this study, we evaluate a tissue-free, methylation-based TF and explore the association with treatment outcomes in RADIOHEAD, a cohort of 1,070 patients with solid tumors receiving standard-of-care immune checkpoint inhibition (ICI) regimens, with blood samples collected prospectively for retrospective analysis. A total of 1,997 baseline and serial on-treatment plasma samples from 627 patients with stage IV cancer were analyzed with an analytically validated next-generation sequencing methylation-based ctDNA assay (Guardant Reveal). The primary outcome measure was real-world progression-free survival (rwPFS). Secondary outcomes included real-world overall survival (rwOS) and the lead time between nonmolecular response (nMR) to rwPFS event. Patients with any decrease in TF while receiving ICI had superior outcomes. Patients with ≥80% decrease in TF at two timepoints or TF below the limit of quantification had longer rwPFS and rwOS than those with <80% decrease [nMR; rwPFS HR, 0.24 (95% confidence interval, 0.19–0.32) P < 0.005; rwOS HR, 0.28 (95% confidence interval, 0.21–0.38) P < 0.005]. nMR was detected prior to clinical progression in 209 patients with a median lead time of 3.03 months. Among 627 patients with stage IV cancer receiving standard-of-care ICI, monitoring with methylation-based TF identified patients who have significantly longer rwPFS and rwOS. Changes in TF on ICI can provide additional response data earlier than imaging alone and support the potential of serial monitoring to inform treatment decisions.
This study found that early decreases in tumor DNA levels in the blood are linked to longer survival in patients with cancer treated with immunotherapy. These findings support the use of blood-based monitoring to help predict treatment response and improve decision-making in real-world cancer care.
